Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trial

Background Guidelines recommend screening for Neisseria gonorrhoeae and Chlamydia trachomatis at three anatomical sites (urethra, anus, and pharynx) every 3 months (3 x 3) in men who have sex with men (MSM) and transgender women taking HIV pre -exposure prophylaxis (PrEP). We present the first randomised controlled trial to compare the effect of screening versus non -screening for N gonorrhoeae and C trachomatis on the incidence of these infections in MSM and transgender women taking PrEP. Methods A multicentre, randomised, controlled trial of 3 x 3 screening for N gonorrhoeae and C trachomatis versus non -screening was done among MSM and transgender women taking PrEP in five HIV reference centers in Belgium. Participants attended the PrEP clinics quarterly for 12 months. N gonorrhoeae and C trachomatis was tested at each visit in both arms, but results were not provided to the non -screening arm, if asymptomatic. The primary outcome was incidence rate of N gonorrhoeae and C trachomatis infections in each arm, assessed in the per -protocol population. Non -inferiority of the non -screening arm was proven if the upper limit of the 95% CI of the incidence rate ratio (IRR) was lower than 125. This trial is registered with ClinicalTrials.gov, NCT04269434, and is completed. Findings Between Sept 21, 2020, and June 4, 2021, 506 participants were randomly assigned to the 3 x 3 screening arm and 508 to the non -screening arm. The overall incidence rate of N gonorrhoeae and C trachomatis was 0155 cases per 100 person -days (95% CI 0128-0186) in the 3 x 3 screening arm and 0205 (95% CI 0171-0246) in the nonscreening arm. The incidence rate was significantly higher in the non -screening arm (IRR 1318, 95% CI 1068-1627). Participants in the non -screening arm had a higher incidence of C trachomatis infections and symptomatic C trachomatis infections. There were no significant differences in N gonorrhoeae infections. Participants in the nonscreening arm consumed significantly fewer antimicrobial drugs. No serious adverse events were reported. Interpretation We failed to show that non -screening for N gonorrhoeae and C trachomatis is non -inferior to 3 x 3 screening in MSM and transgender women taking PrEP in Belgium. However, screening was associated with higher antibiotic consumption and had no effect on the incidence of N gonorrhoeae . Further research is needed to assess the benefits and harms of N gonorrhoeae and C trachomatis screening in this population. Funding Belgian Health Care Knowledge Centre Copyright (c) 2024 Elsevier Ltd. All rights reserved.